Dr. Howard Smith Oncall

Vidcast:  https://www.instagram.com/reel/DHWouikv4B-/University of Maryland virologists, in conjunction with staff at the Vaxart company, now report that a newly developed oral norovirus vaccine candidate is safe and effective.  This vaccine in tablet form, VXA-G1.1-NN, delivers a nonreplicating adenoviral vector that carriers the norovirus G1.1 major capsid protein VP1.  The vaccine underwent phase 1 testing in a group of 65 adults ages 55 to 80 years of age.  The vaccine is well-tolerated, and capable of producing a robust immune response  with both IgG and IgA antibodies appearing at one month and remaining protective for up to 210 days,Norovirus is the number one cause of gastroenteritis in the U.S. triggering 20 million cases per year.  It preys upon older adults, particularly those in nursing homes.   After this oral, easily administered vaccine undergoes further testing including that in a randomized, blinded Phase 3 trial, it will be ready for routine clinical use.  .https://medicalxpress.com/news/202